AEZS vs. AKTX, ATHE, ELAB, MBRX, GHSI, GRTX, ERNA, NCNA, MTEM, and VIRI
Should you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Akari Therapeutics (AKTX), Alterity Therapeutics (ATHE), Elevai Labs (ELAB), Moleculin Biotech (MBRX), Guardion Health Sciences (GHSI), Galera Therapeutics (GRTX), Eterna Therapeutics (ERNA), NuCana (NCNA), Molecular Templates (MTEM), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical preparations" industry.
Akari Therapeutics (NASDAQ:AKTX) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.
Akari Therapeutics has a net margin of 0.00% compared to Akari Therapeutics' net margin of -368.01%. Aeterna Zentaris' return on equity of 0.00% beat Akari Therapeutics' return on equity.
Aeterna Zentaris has a consensus target price of $15.00, indicating a potential upside of 666.79%. Given Akari Therapeutics' higher probable upside, analysts plainly believe Aeterna Zentaris is more favorable than Akari Therapeutics.
In the previous week, Aeterna Zentaris had 1 more articles in the media than Akari Therapeutics. MarketBeat recorded 4 mentions for Aeterna Zentaris and 3 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 0.33 beat Aeterna Zentaris' score of 0.23 indicating that Aeterna Zentaris is being referred to more favorably in the news media.
Akari Therapeutics has higher earnings, but lower revenue than Aeterna Zentaris.
Aeterna Zentaris received 157 more outperform votes than Akari Therapeutics when rated by MarketBeat users. Likewise, 62.54% of users gave Aeterna Zentaris an outperform vote while only 54.93% of users gave Akari Therapeutics an outperform vote.
Akari Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.
5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 0.7% of Aeterna Zentaris shares are held by institutional investors. 61.8% of Akari Therapeutics shares are held by company insiders. Comparatively, 0.1% of Aeterna Zentaris shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Aeterna Zentaris beats Akari Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Aeterna Zentaris News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AEZS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aeterna Zentaris Competitors List
Related Companies and Tools
